PSYCHOSTIMULANT-INDUCED ACTIVITY IS ATTENUATED BY 2 PUTATIVE DOPAMINE RELEASE INHIBITORS

被引:18
作者
CALCAGNETTI, DJ
SCHECHTER, MD
机构
[1] Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown
关键词
DOPAMINE; AMPHETAMINE; CATHINONE; COCAINE; ACTIVITY; ISRADIPINE; CGS-10746B; CALCIUM CHANNEL BLOCKADE; INTRACEREBROVENTRICULAR; RATS; ANTAGONISM;
D O I
10.1016/0091-3057(92)90476-V
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Centrally administered amphetamine (AMPH), cathinone, (CATH), or cocaine (COC) have each been shown to produce elevated activity in rats and this effect is dose responsive. The question remains whether these psychostimulants share a common mechanism of action (i.e., do these psychostimulants act by releasing dopamine to increase activity levels?). Experiments were, therefore, conducted to measure the spontaneous activity of these three centrally administered psychostimulants in rats following pretreatment with two putative dopamine release inhibitors, viz., 5-(4-methyl-I piperazinyl)imidazol(2,1-b) (1,3,5)-benzothiadiazepine maleate [CGS 10746B (CGS); 20 mg/kg)] and 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methyl-ethyl ester [isradipine (ISR); 2.5 mg/kg)]. Rats fitted with chronic indwelling ventricular cannulae received a single dose of ICV-administered CATH (32 mug), AMPH (16 mug), COC (100 mug), or vehicle. Selection of these ICV doses of stimulant drugs was based upon results obtained in preliminary studies that indicated similar elevations of activity. ICV administration of each of these drugs/doses was preceded (20 min) by peripherally administered CGS, ISR, or vehicle. Results show that ICV CATH (32 mug), AMPH (16 mug), COC (100 mug) equieffectively elevate activity (two- to threefold) and that, in each case, this increase was significantly attenuated by pretreatment with CGS or ISR.
引用
收藏
页码:1023 / 1031
页数:9
相关论文
共 46 条
[1]  
ALTAR CA, 1988, N-S ARCH PHARMACOL, V338, P162
[2]   CGS-10746B - AN ATYPICAL ANTIPSYCHOTIC CANDIDATE THAT SELECTIVELY DECREASES DOPAMINE RELEASE AT BEHAVIORALLY EFFECTIVE DOSES [J].
ALTAR, CA ;
WASLEY, AM ;
LIEBMAN, J ;
GERHARDT, S ;
KIM, H ;
WELCH, JJ ;
WOOD, PL .
LIFE SCIENCES, 1986, 39 (08) :699-705
[3]  
BAKSHI VP, 1991, PSYCHOBIOLOGY, V19, P233
[4]  
BOSS R, 1988, PSYCHOPHARMACOLOGY B, V95, P447
[5]  
BOWYER JF, 1990, J PHARMACOL EXP THER, V254, P664
[6]   OPEN TRIAL OF A CALCIUM-ANTAGONIST, NIMODIPINE, IN ACUTE MANIA [J].
BRUNET, G ;
CERLICH, B ;
ROBERT, P ;
DUMAS, S ;
SOUETRE, E ;
DARCOURT, G .
CLINICAL NEUROPHARMACOLOGY, 1990, 13 (03) :224-228
[7]   CONDITIONED PLACE AVERSION FOLLOWING THE CENTRAL ADMINISTRATION OF A NOVEL DOPAMINE RELEASE INHIBITOR CGS 10746B [J].
CALCAGNETTI, DJ ;
SCHECHTER, MD .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (02) :255-259
[8]  
CALCAGNETTI DJ, 1992, BRAIN RES B, V28, P971
[9]   AMPHETAMINE, COCAINE, PHENCYCLIDINE AND NOMIFENSINE INCREASE EXTRACELLULAR DOPAMINE CONCENTRATIONS PREFERENTIALLY IN THE NUCLEUS ACCUMBENS OF FREELY MOVING RATS [J].
CARBONI, E ;
IMPERATO, A ;
PEREZZANI, L ;
DICHIARA, G .
NEUROSCIENCE, 1989, 28 (03) :653-661
[10]  
CARBONI E, 1988, VOLTAGE SENSITIVE IO, P171